Paradiem, LLC Genmab A/S Transaction History

Paradiem, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 03, 2022	SELL	$35.87 - $47.12 $1.04 Million - $1.36 Million	-28,904 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$41.55 - $48.72 $52,643 - $61,728	1,267 Added 4.58%	28,904 $1.3 Million
Q2 2021 Aug 16, 2021	BUY	$32.88 - $44.57 $57,474 - $77,908	1,748 Added 6.75%	27,637 $1.29 Million
Q1 2021 May 18, 2021	BUY	$30.92 - $44.4 $347,015 - $498,301	11,223 Added 76.52%	25,889 $921,000
Q4 2020 Jan 29, 2021	BUY	$33.66 - $40.76 $493,657 - $597,786	14,666 New	14,666 $590,000

241

47.6M

31.3K

38.7K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $16.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Paradiem, LLC, based on Form 13F filings with the SEC.

Stay updated on Paradiem, LLC with notifications on news.